drugset
drugset / Trial / NCT05341492

EGFR/B7H3 CAR-T on Lung Cancer and Triple Negative Breast Cancer

NCT05341492 ↗

Phase 0 Recruiting 30 enrolled Second Affiliated Hospital of Guangzhou Medical University
NaSingle-groupOpen-labelTreatment

Summary

This study is a single-arm, open, exploratory clinical study to evaluate the safety and efficacy of EGFR/B7H3 CAR-T in patients with EGFR/ B7H3-positive advanced solid tumors (lung cancer and triple-negative breast cancer)

Timeline

Start
2022-05-01
Primary completion
2030-05-01
Completion
2035-05-01

Drugs

EvaluationDrugModalityDoseRoute
Subject EGFR/B7H3 CAR-T Cell therapy 2e+06 cells/kg —

Indications

triple-negative breast carcinoma